CARL
$11.70
Carlsmed, Inc., a commercial-stage medical technology company, designs, manufactures, and markets AI-enabled personalized spine surgery solutions.
Intraday
Recent News
Carlsmed Unveils Personalized Spine Platform, Targets $70M-$75.5M 2025 Revenue at Conference
Carlsmed (NASDAQ:CARL) used its presentation at Canaccord Genuity’s Musculoskeletal Conference to outline its mission to improve outcomes and reduce the cost of spine surgery by lowering reoperation rates in spine fusion procedures through a personalized, data-driven technology platform. CEO Mike Co
Carlsmed Q4 Earnings Call Highlights
Carlsmed (NASDAQ:CARL) reported rapid growth in the fourth quarter and full year 2025, highlighting record revenue, gross margin expansion, and increasing surgeon adoption as the company scaled its personalized spine surgery platform following its July initial public offering. 2025 highlights: reve
Carlsmed Inc (CARL) Q4 2025 Earnings Call Highlights: Record Revenue Growth Amidst Financial ...
Carlsmed Inc (CARL) reports impressive revenue growth and operational efficiency, but faces ongoing financial hurdles as it navigates market expansion.
Bullish Carlsmed Insiders Loaded Up On US$8.10m Of Stock
In the last year, multiple insiders have substantially increased their holdings of Carlsmed, Inc. ( NASDAQ:CARL...
CARL Launches Aprevo Cervical Platform for Personalized Spine Surgery
Carlsmed launches personalized aprevo cervical platform with early cases and new reimbursement support driving momentum in spine surgery.